En-kang Pharma Completes Tens of Millions of Yuan in Strategic Financing, with T-Capital as Financial Advisor
On December 20, 2021, En-kang Pharma Technology (Guangzhou) Co., Ltd. (hereinafter referred to as “En-kang Pharma”) announced the completion of a strategic financing of tens of millions of RMB, with T-Capital acting as the financial advisor for this round.
The funds from this financing round will be primarily used to accelerate the R&D of the company’s innovative targeted anti-tumor new drugs.
As a pharmaceutical R&D company focused on the development of innovative anti-cancer new drugs and drug formulations, En-kang Pharma conducts innovative drug R&D around novel anti-cancer drug targets. This financing round provides further capital support for the company to advance its innovative drug R&D pipeline and also reflects the capital market’s attention to innovative pharmaceutical R&D projects.
Transaction Overview
| Item | Information |
|---|---|
| Transaction Date | December 20, 2021 |
| Transaction Type | Strategic Financing |
| Financing Size | Tens of millions of RMB |
| Company Name | En-kang Pharma Technology (Guangzhou) Co., Ltd. |
| Industry | Healthcare / Biopharmaceuticals |
| Core Focus | R&D of innovative anti-tumor drugs |
| Role in this Round | T-Capital acted as financial advisor |
| Use of Funds | To accelerate the R&D of innovative targeted anti-tumor new drugs |
T-Capital acted as the financial advisor to En-kang Pharma in this transaction, assisting the company in advancing this round of strategic financing.
I. En-kang Pharma: Focusing on Innovative Anti-cancer Drug R&D
En-kang Pharma is a pharmaceutical R&D company dedicated to the development of innovative anti-cancer new drugs and drug formulations.
The company was co-founded by the research team of Professor Chun Liang from the Division of Life Science at the Hong Kong University of Science and Technology and the research team of Professor Zhihong Jiang from the Institute for Applied Research in Medicine and Health at the Macau University of Science and Technology.
The company has R&D laboratories and pilot production workshops in Hong Kong, Macau, Guangzhou, and Foshan, with the Guangzhou R&D center established on Guangzhou International Bio Island in October 2015.
Relying on university research teams and R&D platforms, En-kang Pharma focuses on the development of innovative anti-cancer drugs and related formulations.
II. Innovative Drug R&D Centered Around DRIPs Targets
En-kang Pharma, with its core technology of highly selective new target anti-cancer drug screening, focuses on the R&D of original small molecule and nucleic acid anti-cancer drugs targeting DNA replication initiation proteins (DRIPs).
As of this financing, the company has applied for 15 domestic and international invention patents, 7 of which have been granted.
This technology and intellectual property layout forms an important foundation for the company’s innovative drug R&D.
For innovative drug companies, the R&D platform, core targets, intellectual property, and candidate drug pipeline together form an important basis for subsequent financing and industrial cooperation.
III. Core Innovative Drug EN002 Enters Clinical Development Stage
En-kang Pharma’s first innovative DRIPs target, a First-in-Class anti-cancer drug, EN002 gel, has completed preclinical studies.
In August 2021, EN002 gel received a clinical trial approval for Phase I/II in China, intended for the treatment of non-melanoma skin cancer and precancerous lesions.
From an R&D stage perspective, this strategic financing occurred after the company’s core innovative drug had completed preclinical studies and entered the clinical development stage.
The financing funds are mainly used to accelerate the R&D of innovative targeted anti-tumor new drugs, providing financial support for subsequent R&D work.
IV. Core Use of This Financing: Accelerating Innovative Drug R&D
Innovative drug R&D is characterized by long R&D cycles, continuous capital investment, and high R&D risks.
For innovative drug companies in the clinical development stage, financing funds typically need to serve subsequent R&D and clinical advancement.
The funds from En-kang Pharma’s this financing round are mainly used for:
- Accelerating the R&D of innovative targeted anti-tumor new drugs;
- Advancing the core innovative drug R&D pipeline;
- Supporting subsequent clinical development;
- Providing continuous financial support for innovative drug R&D.
This financing round is therefore not only a capital supplement but also serves the company’s innovative drug R&D strategy.
V. T-Capital Acts as Financial Advisor for This Round of Financing
In this strategic financing, T-Capital acted as the financial advisor to En-kang Pharma.
For innovative drug companies, financing is not just about finding funds.
The capital needs of companies differ at different R&D stages, and the focus of potential investors also changes with R&D progress.
From the company’s perspective, innovative drug financing typically requires a clear presentation of:
- Core R&D technology;
- Product pipeline;
- Clinical development stage;
- Intellectual property;
- Target indications;
- Market potential;
- Subsequent R&D plans;
- Use of funds plan.
T-Capital provides advisory services for corporate financing, M&A, licensing, and strategic cooperation around the capital transaction needs in the healthcare sector.
VI. Innovative Drug Companies Need to Translate “Technical Value” into “Capital Language”
For early-stage and growth-stage innovative drug companies, technological R&D capability is an important basis of corporate value, but the capital market needs to further understand:
What is the clinical value of this technology? At what R&D stage is the product? How much funding is needed in the future? What is the next value inflection point?
Therefore, the innovative drug financing process usually needs to form a clear logical chain of the company’s:
Technology → Product → Clinical → Intellectual Property → Commercial Potential → Capital Needs
For healthcare companies with innovative technology and R&D pipelines that are entering the clinical development stage, how to accurately position the financing story, identify target investors, and design the transaction path are key issues to be solved in the financing process.
VII. From R&D Pipeline to Financing Transaction: Innovative Drug Companies Need to Plan Their Capital Path in Advance
The capital needs of innovative drug companies often change with the R&D stage.
A company may experience:
Scientific Research Achievements → Technology Platform → Candidate Drugs → Preclinical Research → Clinical Development → Registration Submission → Commercialization
Different stages correspond to different funding needs, investor types, and capital strategies.
Therefore, companies should not only start looking for financing when funds are tight.
A more effective approach is to plan in advance:
- Next-stage R&D goals;
- Estimated funding needs;
- Key value inflection points;
- Potential investors;
- Financing time window;
- Subsequent capital path.
This can make financing more closely aligned with the company’s R&D plan.
VIII. Transaction Inspiration: Healthcare Financing Requires the Combination of Industry and Capital
The En-kang Pharma financing case reflects an important characteristic of healthcare corporate financing:
Innovative technology is the foundation, R&D progress is value verification, and capital provides resources for the next stage of R&D.
For innovative drug companies, financing transactions not only need to focus on the amount of financing, but also need to consider whether investors can understand the company’s technology route, R&D pipeline, and long-term strategy.
In addition to providing funds, strategic investors may also bring:
- Industrial resources;
- Technical cooperation;
- Commercialization resources;
- Subsequent financing resources;
- Strategic cooperation opportunities.
Therefore, selecting investors and designing financing plans are themselves part of a company’s long-term strategy.
Why do innovative drug companies need professional financing advisors?
Innovative drug financing usually involves multiple dimensions such as technology, clinical, intellectual property, market, and capital markets.
A professional financing advisor can help a company further sort out:
1. Corporate Value Proposition
Clarify the company’s core technology, product pipeline, and competitive advantages.
2. Financing Strategy
Determine financing goals based on the R&D stage and funding needs.
3. Investor Matching
Find investors who match the company’s technology direction, development stage, and strategic goals.
4. Transaction Materials
Translate R&D and technical information into business and capital logic that investors can quickly understand.
5. Transaction Execution
Assist the company in advancing investor communication, transaction negotiations, and the financing process.
For healthcare companies in the R&D, clinical, or early commercialization stages, the financing strategy needs to be consistent with the company’s long-term development plan.
T-Capital Healthcare Financing Advisory Services
T-Capital focuses on capital transactions and strategic consulting in the healthcare sector, providing financing and industrial capital services around the different development stages of companies.
If your company is conducting:
- Innovative drug financing
- Medical device financing
- Biopharmaceutical financing
- Strategic financing
- Industrial financing
- Equity financing
- License / BD
- M&A and divestitures
- Cross-border healthcare transactions
You can communicate with the T-Capital team about your company’s capital needs and development plans.
If you are looking for a financing advisor in the healthcare sector, you are welcome to contact T-Capital to discuss your financing stage, funding needs, and potential capital path.
Transaction Keywords
En-kang Pharma Financing | En-kang Pharma Strategic Financing | Healthcare Financing | Innovative Drug Financing | Biopharmaceutical Financing | Anti-tumor Drug Financing | Innovative Drug Company Financing | Pharmaceutical Company Financing Advisor | Healthcare Financial Advisor | Strategic Financing Advisor | T-Capital
Frequently Asked Questions (FAQ)
When did En-kang Pharma complete this round of financing?
En-kang Pharma announced the completion of this strategic financing of tens of millions of RMB on December 20, 2021.
Who was the financial advisor for En-kang Pharma in this round of financing?
T-Capital acted as the financial advisor for this round of financing.
What are the main uses of the funds from this financing round for En-kang Pharma?
The funds from this financing round are mainly used to accelerate the R&D of the company’s innovative targeted anti-tumor new drugs.
What is the main business of En-kang Pharma?
En-kang Pharma is a pharmaceutical R&D company focused on the development of innovative anti-cancer new drugs and drug formulations.
What is the core R&D direction of En-kang Pharma?
The company, with its core technology of highly selective new target anti-cancer drug screening, focuses on the R&D of original small molecule and nucleic acid anti-cancer drugs targeting DNA replication initiation proteins (DRIPs).
What is EN002?
EN002 is En-kang Pharma’s first innovative DRIPs target, a First-in-Class anti-cancer drug. The product has completed preclinical studies and received a clinical trial approval for Phase I/II in China in August 2021, intended for the treatment of non-melanoma skin cancer and precancerous lesions.
What are the R&D and intellectual property foundations of En-kang Pharma?
As of this financing round, the company has applied for 15 domestic and international invention patents, 7 of which have been granted.
Why do healthcare companies need financing advisors?
Healthcare company financing usually involves multiple dimensions such as R&D stage, product pipeline, intellectual property, clinical progress, market space, and capital needs. A professional financing advisor can assist the company in value positioning, financing strategy design, investor matching, and transaction execution.
What healthcare capital services does T-Capital provide?
T-Capital provides capital transaction and strategic consulting services for healthcare companies, including private financing, M&A and divestitures, License & BD, strategic cooperation, and cross-border transactions.